Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 11/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813950 | 0.99 | POLB (0.45) | POLBHPGDTDP1S1PR3PTGER4 | |
| SCHEMBL6702024 | 0.90 | TRPA1 (0.48) | POLBHPGDTDP1TRPA1CNR2 | |
| SCHEMBL6703216 | 0.86 | ADORA2B (0.38) | HPGDGPR18 | |
| SCHEMBL6682303 | 0.82 | S1PR3 (0.47) | S1PR3PTGER4TRPA1GPR18MAPT | |
| SCHEMBL6700366 | 0.81 | S1PR3 (0.44) | S1PR3PTGER4TRPA1 | |
| SCHEMBL6702256 | 0.81 | TRPA1 (0.49) | S1PR3PTGER4TRPA1 | |
| SCHEMBL6701275 | 0.78 | IDO1 (0.48) | POLBHPGDTDP1PTGER4CNR2 | |
| SCHEMBL6289370 | 0.78 | MMP13 (0.46) | PTGER4MAPT | |
| SCHEMBL6701186 | 0.77 | MMP13 (0.41) | POLBHPGDTDP1GPR18MAPT | |
| SCHEMBL6700333 | 0.77 | S1PR3 (0.48) | POLBS1PR3PTGER4TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | claimed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | POLB 678/4885HPGD 323/4885TDP1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.